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Evidence summary
As many as 30% of patients with major de-
pression fail to respond to treatment with a 
single antidepressant drug given in adequate 
dosage for an appropriate period.1 Pharma-
cologic approaches such as switching anti-
depressant classes are often attempted fi rst, 
followed by augmentation with another 
agent if needed.
Th e most widely studied medications 
used for augmentation are lithium and T3.2 An 
important limitation to their use is that most 
of the supporting evidence comes from stud-
ies of patients who didn’t respond initially to 
tricyclic antidepressants.
Lithium boosts response 
to antidepressants
A 2007 meta-analysis of 10 augmentation stud-
ies reported that adding lithium to various an-
tidepressant agents increased the chances of 
clinical response 3-fold relative to placebo (odds 
ratio [OR]=3.11; 95% confi dence interval [CI], 
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1.80-5.37), yielding a num-
ber needed to treat (NNT) 
of 5.3 Th e mean response 
rate was 41.2% in the lithi-
um group and 14.4% in the 
placebo group (P<.001). Th e 
meta-analysis included only 
RCTs that enrolled subjects 
with unipolar or bipolar 
disorder (depressive phase) 
who were treated with any 
antidepressant plus lithium 
in any dose compared with 
placebo.
A previous meta-
analysis published in 1999 
concluded that a lithium 
dose suffi  cient to produce serum levels of at 
least 0.5 mEq/L and a minimum treatment 
duration of 2 weeks resulted in a pooled OR of 
response to lithium augmentation compared 
with placebo of 3.31 (95% CI, 1.46-7.53).4 Lith-
ium augmentation is a reasonable alternative 
for depressed patients who don’t respond to 
conventional antidepressants.
T3 works well with tricyclics, but what 
about newer antidepressants?
A 1996 meta-analysis of 8 studies with a to-
tal of 292 patients found that patients who 
received T3 augmentation of tricyclic an-
tidepressant therapy were twice as likely to 
respond as controls (relative response=2.09; 
95% CI, 1.31-3.32).5 Th e corresponding pooled 
absolute diff erence in response rate was 23.2% 
with a corresponding NNT of 4.3.
T3 dosage in the studies ranged from 25 
to 50 mcg/day and duration varied from 7 to 
35 days. Analysis of data from RCTs alone pro-
duced a lower pooled relative response of 1.53 
EVIDENCE-BASED ANSWER
A yes, lithium, triiodothyronine (T), and atypical  antipsychotics are all eff ective adjuncts. Lithium 
(serum levels >0.5 mEq/L) can produce clinical improve-
ment when added to ineff ective antidepressant treatment 
(strength of recommendation [SOR]: A, meta-analysis of 
randomized controlled trials [RCTs]).
Th yroid supplementation using T3 at doses no higher 
than 50 mcg per day also increases the eff ectiveness of an-
tidepressant therapy (SOR: B, meta-analysis of RCT and co-
hort studies).
Atypical antipsychotic agents are less eff ective adjuncts 
for patients with treatment-resistant major depressive disor-
der (SOR: B, meta-analysis of RCT and cohort studies). 
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over lithium 
because it has 
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effects.
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remission and response were 47.4% vs 22.3% 
(NNT=4) and 57.2% vs 35.4% (NNT=4.6), 
respectively.
Although the meta-analysis found no 
diff erence in overall discontinuation rates 
(P=.929), the rate of discontinuation because of 
adverse events was lower among placebo-treat-
ed patients (RR=3.38, P<.0001). Th ese results 
suggest a role for atypical antipsychotic agents 
in augmenting standard antidepressants for 
treatment-resistant major depressive disorder.
Recommendations 
Both the American Psychiatric Association7 and 
the Institute for Clinical Systems Improvement8
recommend considering a trial of lithium or 
thyroid augmentation for patients who respond 
only partially to initial antidepressant therapy. 
Many experienced clinicians consider lithium 
to be the most eff ective adjunct. Th e APA cau-
tions, however, that its Major Depressive Disor-
der Practice Guideline, published in 2000, is no 
longer current.9 An update is expected by the 
end of the year.
Other options include maximizing the 
initial treatment, switching to another agent, 
or augmenting initial treatment with another 
antidepressant agent or psychotherapy. Be-
fore prescribing any additional treatments 
for patients who fail to respond to initial an-
tidepressant therapy, however, primary care 
physicians need to be mindful of the fact that 
empirical data regarding the relative eff ective-
ness of these strategies are limited—and that 
they should consider whether the patients 
they’re treating have bipolar—rather than 
unipolar—depression.                
(95% CI, 0.70-3.35) and an NNT of 12.5. A major 
drawback of T3 augmentation is that little infor-
mation is available about its effi  cacy in combi-
nation with newer antidepressant agents.
T3 may have a slight edge 
over lithium in side effects
As a part of the Sequenced Treatment Alter-
natives to Relieve Depression (STAR*D) study, 
lithium and T3 augmentation were compared 
directly in patients who had failed 2 medica-
tion treatments for depression. A total of 142 
adult outpatients with nonpsychotic major 
depressive disorder who had not achieved re-
mission with (or who were intolerant to) cital-
opram, and who similarly had no luck with 
either a therapeutic switch or an augmenta-
tion trial, were randomly assigned to lithium 
or T3 augmentation for as long as 14 weeks.
After a mean of 9.6 weeks of treatment, 
remission rates were 15.9% with lithium and 
24.7% with T3, although the diff erence be-
tween the 2 drugs wasn’t statistically signifi -
cant. Because T3 has fewer side eff ects and is 
easier to use, the researchers suggested that it 
may have a slight advantage over lithium.
Atypical antipsychotic agents 
are another alternative
A 2007 meta-analysis of 10 clinical trials in-
volving 1500 outpatients studied the effi  cacy 
of augmenting standard antidepressants with 
atypical antipsychotic agents to treat resistant 
major depressive disorder.6 Across the trials, 
the pooled risk ratio (RR) for remission was 
1.75 (95% CI, 1.36-2.24) and for response rates 
was 1.35 (95% CI, 1.13-1.63). Pooled rates for 
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